Ruhr-Universität Bochum
- Address
- lock Available on a paid plan
Ruhr-Universität Bochum - Advanced Wound Healing Research
Ruhr-Universität Bochum is actively engaged in innovative regenerative medicine research, with particular emphasis on advancing treatment options for challenging wound healing conditions. The center focuses on developing novel therapeutic approaches for patients who have exhausted conventional treatment options.
- Stem cell therapy for chronic venous ulcers
- Regenerative medicine applications in wound care
- Treatment of therapy-resistant non-healing wounds
The research center's work in chronic venous ulcers (CVU) represents a significant advancement in addressing long-term, non-healing leg wounds. By investigating allogeneic stem cell products administered topically, the institution is pioneering approaches to promote complete wound closure in patients with therapy-resistant conditions, combining rigorous safety monitoring with efficacy assessments to establish new standards in wound healing therapeutics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ruhr-Universität Bochum
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Allogeneic Skin-Derived ABCB5-Positive Dermal Mesenchymal Stromal Cells in Therapy-Resistant Chronic Venous Ulcers | Rheacell GmbH & Co. KG | Phase III | Not Recruiting | Jan 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells | 1 | Unknown | 2025-01-16 | 2025-01-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.